BEAM THERAPEUTICS INC (BEAM)

Company Profile

Beam Therapeutics, Inc. develops and commercializes DNA base editing technologies for the treatment of human disease. The company is headquartered in Cambridge, Massachusetts and currently employs 507 full-time employees. The company went IPO on 2020-02-06. The firm operates a fully integrated platform for precision genetic medicines. Its base editing technology enables a differentiated class of precision genetic medicines that target a single base in the genome without making a double-stranded break in the deoxyribonucleic acid (DNA). The firm is advancing its base editing technology across three disease-area portfolios: hematology, immunology/oncology and genetic diseases. Its clinical-stage programs include BEAM-101, BEAM-201, BEAM-301 and BEAM-302. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy designed to offer a profile, incorporating base edits that are intended to mimic single nucleotide polymorphisms seen in individuals with hereditary persistence of fetal hemoglobin (HPFH). BEAM-201 is a development candidate comprised of T cells.

Company Info

BEAM THERAPEUTICS INC

238 Main Street

Cambridge MASSACHUSETTS 02139

P: 18573278775

CEO: John Evans

Employees: 507

Website: https://beamtx.com/